Levi & Korsinsky Alerts Iovance Biotherapeutics Investors on Class Action Lawsuit and Important Deadlines
On July 8, 2025, Levi & Korsinsky, LLP released a significant notification for shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), shedding light on a class action securities lawsuit currently underway. This disclosure is particularly pertinent for investors who may have experienced losses due to alleged securities fraud that occurred between May 9, 2024, and May 8, 2025.
The ongoing class action lawsuit aims to recover losses for Iovance investors who were adversely impacted by misleading statements made by the company's executives. According to the complaint, during the designated class period, Iovance provided investors with overwhelmingly optimistic projections regarding the company's growth and prospects while simultaneously concealing material information that could have influenced investor decision-making. Specifically, the suit contends that Iovance was unable to adequately generate demand or fully capitalize on the existing demand for its treatments through its approved treatment centers.
The circumstances escalated on July 25, 2024, when Iovance announced its second quarter fiscal results for 2024, which were far less favorable than expected. The company lowered its revenue guidance for the entire fiscal year due to several operational challenges, including maintenance-related disruptions and lower-than-anticipated sales. Following these revelations, the stock price suffered dramatically. On May 8, 2025, closing at $3.17 per share, it plummeted to $1.75 the very next day—marking a staggering decline of nearly 45% in just 24 hours.
Investors who sustained losses during this timeframe have a critical deadline approaching. By July 14, 2025, individuals wishing to serve as lead plaintiffs in the class action must file a request with the court. However, it is crucial to note that participating in any potential recovery does not necessitate serving in this capacity.
Importantly, investors who qualify for the class action may receive compensation without any financial burden, as there are no out-of-pocket costs or fees involved in joining the suit.
With a rich history spanning over two decades, the legal team at Levi & Korsinsky has secured substantial settlements for shareholders, amassing hundreds of millions of dollars in recoveries. The firm specializes in complex securities litigation, boasting a dedicated team of over 70 professionals committed to serving the interests of their clients. Out of over 50 law firms, Levi & Korsinsky has repeatedly been recognized as one of the leading firms in the nation for securities litigation, further solidifying their expertise in this area.
For additional details regarding the class action or to seek counsel, shareholders can reach out to Levi & Korsinsky, LLP via their New York City office. Investors may contact Joseph E. Levi, Esq., or Ed Korsinsky, Esq., at 33 Whitehall Street, 17th Floor, New York, NY 10004. Inquiries can also be directed via email or phone.
The class action lawsuit against Iovance Biotherapeutics represents a crucial opportunity for aggrieved investors to potentially recover their losses. As the deadline approaches, it is imperative for affected shareholders to take swift action to protect their interests within the legal framework of this case. Staying informed and understanding your rights can make the difference in such complex financial matters.
Class Action Overview
The ongoing class action lawsuit aims to recover losses for Iovance investors who were adversely impacted by misleading statements made by the company's executives. According to the complaint, during the designated class period, Iovance provided investors with overwhelmingly optimistic projections regarding the company's growth and prospects while simultaneously concealing material information that could have influenced investor decision-making. Specifically, the suit contends that Iovance was unable to adequately generate demand or fully capitalize on the existing demand for its treatments through its approved treatment centers.
The circumstances escalated on July 25, 2024, when Iovance announced its second quarter fiscal results for 2024, which were far less favorable than expected. The company lowered its revenue guidance for the entire fiscal year due to several operational challenges, including maintenance-related disruptions and lower-than-anticipated sales. Following these revelations, the stock price suffered dramatically. On May 8, 2025, closing at $3.17 per share, it plummeted to $1.75 the very next day—marking a staggering decline of nearly 45% in just 24 hours.
Important Next Steps
Investors who sustained losses during this timeframe have a critical deadline approaching. By July 14, 2025, individuals wishing to serve as lead plaintiffs in the class action must file a request with the court. However, it is crucial to note that participating in any potential recovery does not necessitate serving in this capacity.
No Cost to Investors
Importantly, investors who qualify for the class action may receive compensation without any financial burden, as there are no out-of-pocket costs or fees involved in joining the suit.
Why Levi & Korsinsky?
With a rich history spanning over two decades, the legal team at Levi & Korsinsky has secured substantial settlements for shareholders, amassing hundreds of millions of dollars in recoveries. The firm specializes in complex securities litigation, boasting a dedicated team of over 70 professionals committed to serving the interests of their clients. Out of over 50 law firms, Levi & Korsinsky has repeatedly been recognized as one of the leading firms in the nation for securities litigation, further solidifying their expertise in this area.
Contact Information
For additional details regarding the class action or to seek counsel, shareholders can reach out to Levi & Korsinsky, LLP via their New York City office. Investors may contact Joseph E. Levi, Esq., or Ed Korsinsky, Esq., at 33 Whitehall Street, 17th Floor, New York, NY 10004. Inquiries can also be directed via email or phone.
Conclusion
The class action lawsuit against Iovance Biotherapeutics represents a crucial opportunity for aggrieved investors to potentially recover their losses. As the deadline approaches, it is imperative for affected shareholders to take swift action to protect their interests within the legal framework of this case. Staying informed and understanding your rights can make the difference in such complex financial matters.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.